Opendata, web and dolomites

TRAIN-HEART SIGNED

TRAIN-HEART

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRAIN-HEART project word cloud

Explore the words cloud of the TRAIN-HEART project. It provides you a very rough idea of what is the project "TRAIN-HEART" about.

supervision    entrepreneurial    excellent    disease    coding    tissue    detrimental    harness    expand    provides    academic    training    rna    international    critical    transferable    innovative    remodelling    curative    exception    strategies    rnas    pathogenesis    cutting    15    substantially    insights    stress    individual    train    molecules    therapy    specificity    promise    fellows    envisioned    complemented    employability    chronic    functional    arrangements    proposition    therapeutic    teams    generation    phd    brings    act    momentous    biology    horizons    keen    companies    biotech    content    skills    ischemic    clinic    heart    trainings    science    edge    underlying    chemically    cardiovascular    multidisciplinary    genomics    scientific    accelerate    specialised    therapies    transplantation    efficacy    causes    micrornas    oligonucleotides    innovation    cardiac    tolerability    synergies    right    treatment    network    therapeutics    minded    active    league    treating    hold    modified    intersectoral    combination    encourage    drug    regulators   

Project "TRAIN-HEART" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙940˙388 €
 EC max contribution 3˙940˙388 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2023-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 531˙239.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 606˙345.00
3    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) participant 522˙999.00
4    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 505˙576.00
5    UNIVERSIDADE DO PORTO PT (PORTO) participant 475˙440.00
6    UNIVERSITE LYON 1 CLAUDE BERNARD FR (VILLEURBANNE CEDEX) participant 274˙802.00
7    MIRABILIS THERAPEUTICS BV NL (MAASTRICHT) participant 265˙619.00
8    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 252˙788.00
9    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 252˙788.00
10    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 252˙788.00
11    ACCELERO BIOANALYTICS GMBH DE (BERLIN) partner 0.00
12    DESCIN BV NL (Vinkeveen) partner 0.00
13    EHT TECHNOLOGIES GMBH DE (HAMBURG) partner 0.00
14    HARTERAAD NL (S-GRAVENHAGE) partner 0.00
15    KANEKA EUROGENTEC BE (SERAING) partner 0.00
16    SOCIETE EUROPEENNE DE CARDIOLOGIE FR (BIOT SOPHIA ANTIPOLIS) partner 0.00

Map

 Project objective

TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery, specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA therapeutics to the clinic.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRAIN-HEART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRAIN-HEART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

TACT (2020)

Targeted Anti-Cancer Therapies

Read More  

NEWAVE (2019)

Next Water Governance

Read More  

DESIGN-EID (2020)

Defect Simulation and Material Growth of III-V Nanostructures- European Industrial Doctorate Program

Read More